Kynam Capital Management, LP Relmada Therapeutics, Inc. Transaction History
Kynam Capital Management, LP
- $1.22 Billion
- Q3 2024
A detailed history of Kynam Capital Management, LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 300,000 shares of RLMD stock, worth $114,000. This represents 0.17% of its overall portfolio holdings.
Number of Shares
300,000Holding current value
$114,000% of portfolio
0.17%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
81Shares Held
12.3MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$494,8170.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$477,5470.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$450,8510.01% of portfolio
-
Parsons Capital Management Inc1MShares$381,0240.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$278,3120.33% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $10.9M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...